DSGN

At a glance

Design Therapeutics, Inc. (DSGN) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Carlsbad, United States and has 55 employees. The company is worth $656.48M. Revenue was $0 in fiscal 2025. It reported a net loss of $69.79M. The share price is 39.2% below its 52-week high of $17.25. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Steve Cohen (Point72 Asset Management), at $34.24M. In that quarter, 2 of them reduced the position. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$656.48M

P/E

—

Forward P/E

—

P/B

3.3x

Dividend yield

0.00%

Payout

—

EPS

-$1.15

ROE

-34.13%

Profit margin

0.00%

Revenue growth

—

Beta

1.69

52-week high

$17.25

52-week low

$5.40

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• SC
  Steve Cohen− Reduced

  Point72 Asset Management · Q2 2026
  $34.24M

  2.37M shares · 0.1% of portfolio
• RT
  Renaissance TechnologiesHeld

  Renaissance Technologies · Q2 2026
  $5.61M

  387.91K shares · 0.0% of portfolio
• IE
  Israel EnglanderHeld

  Millennium Management · Q2 2026
  $2.14M

  147.71K shares · 0.0% of portfolio

Indicators, year by year

The last 5 closed years, each at that year’s closing price and reported numbers.

Median of the years shown; P/E years above 200x are left out.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company